Tests have been completed on the HEPLISAV-B vaccine, three doses of which result in immunity to hepatitis B in carriers of the human immunodeficiency virus. The HIV Clinical Trials Group (ACTG) press office announced. Hepatitis B often affects carriers of HIV. Our study showed that immunocompromised patients who had not previously been infected with this type of hepatitis were completely protected from infection after three injections of the HEPLISAV-B vaccine. This shows the tremendous impact this vaccine will have on the lives of HIV-infected people around the world, said ACTG Chair Judith Carrier. Hepatitis B is more contagious than HIV, with its particles able to survive outside the human body for long periods of time. Most people's immune systems can usually cope with the infection on their own, but for individuals with weakened immune systems, it poses a serious threat. The HEPLISAV-B vaccine was created in mid-2010 by the American company Dynavax. It was approved for use in the U.S. and Europe in May 2020. It consists of a solution of recombinant hepatitis B virus envelope proteins, as well as a set of immune stimulating substances. ACTG researchers tested the immunogenicity and safety of the vaccine in clinical trials. Sixty-eight carriers of the immunodeficiency virus from the United States, South Africa, and Thailand participated. All were taking antiretroviral drugs before the experiment and were not infected with hepatitis B. Observations showed that consecutive administration of three doses of HEPLISAV-B vaccine resulted in the formation of antibodies to hepatitis B envelope proteins in all participants of the experiment, regardless of the severity of immunodeficiency, as well as age, sex, and ethnicity.